in phase 1, first-in-human, ascending single-dose, placebo (pbo)-controlled, double-blind study evaluated the safety and efficacy of evinacumab administered subcutaneously (sc) or intravenously (iv) in subjects with elevated tgs (150≤ tg ≤450 mg/dl) and/or ldl-c (≥100 mg/dl). evinacumab effected dose-responsive reductions in tg (maximum reduction on day 4) with median % changes from baseline of -1.0% to -75.0% from low to high dose vs +9.0% for pbo iv [p<0.0001]) and ldl-c (mean % changes of ldl-c from baseline on day 11 were -3.4% to -25.5% from low to high dose vs -0.4% for pbo iv [p=0.0013]).